Clinical Trial Update: TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for TACE plus Ivonescimab in unresectable non-metastatic hepatocellular carcinoma; the study status is Not Yet Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1 | Status: NOT_YET_RECRUITING